Achim, A, Maziade, M, Raymond, E, Olivier, D, Merette, C, Roy, M-A. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull
2011; 37: 811–21.
Braga, RJ, Reynolds, GP, Siris, SG. Anxiety comorbidity in schizophrenia. Psychiatry Res
2013; 210: 1–7.
Fusar-Poli, P, Nelson, B, Valmaggia, L, Yung, AR, McGuire, PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull
2014; 40: 120–31.
Jones, P, Rodgers, B, Murray, R, Marmot, M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet
1994; 344: 1398–402.
Cunningham Owens, DG, Miller, P, Lawrie, SM, Johnstone, EC. Pathogenesis of schizophrenia: a psychopathological perspective. Br J Psychiatry
2005; 186: 386–93.
Jones, HJ, Stergiakouli, E, Tansey, KE, Hubbard, L, Heron, J, Cannon, M, et al Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. JAMA Psychiatry
2016; 73: 221–8.
Smith, DJ, Escott-Price, V, Davies, G, Bailey, ME, Colodro-Conde, L, Ward, J, et al. Genome-wide analysis of over 106,000 individuals identifies 9 neuroticism-associated loci. Mol Psychiatry
2016; 21: 749–57.
Schneider, M, Debbane, M, Basset, AS, Chow, EW, Fung, WL, van den Bree, M, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry
2014; 171: 627–39.
Birchwood, M, Spencer, E. Early intervention in psychotic relapse. Clin Psychol Rev
2001; 21: 1211–26.
Cornblatt, BA, Lencz, T, Smith, CW, Olsen, R, Auther, AM, Nakayama, E, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry
2007; 68: 546–57.
Du, Y, Grace, AA. Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology
2013; 38: 1881–8.
Helfer, B, Samara, MT, Huhn, M, Klupp, E, Leucht, C, Zhu, Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry
2016; 173: 876–86.
Carpenter, WT, Buchanan, RW, Kirkpatrick, B, Breier, AF. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry
1999; 156: 299–303.